Abstract
The use of oral antiplatelet therapy in reducing vascular events has been extensively studied. Currently available oral antiplatelet agents include aspirin and the thienopyridine P2Y12 receptor antagonists. These classes are combined frequently in the setting of acute coronary syndrome and percutaneous coronary intervention (PCI). Resistance to either or both of these agents is a major concern, as antiplatelet resistance has been linked to an increase in thrombotic events and worse clinical outcomes. As a result, there is a need for newer, more effective antiplatelet agents to address the limitations of currently available therapy. Prasugrel, a third generation thienopyridine, has been approved by both the FDA and European Commission. Two additional P2Y12 agents, ticagrelor and cangrelor are in advanced stages of development. The possible advantages of prasugrel over clopidogrel include a faster onset of action, reduced inter-patient variability and more potent platelet inhibition. Ticagrelor is an oral reversible P2Y12 antagonist with greater platelet inhibition compared with clopidogrel. Cangrelor is being developed as an intravenous P2Y12 antagonist with a very fast onset and offset, which may offer advantages particularly in the setting of coronary intervention. These emerging antiplatelet agents may offer advantages such as faster onset of action, greater potency and reversibility of platelet inhibition. This article summarizes the available clinical data on the upcoming P2Y12 antiplatelet agents in the treatment of coronary artery disease.
Keywords: P2Y12 receptor antagonists, prasugrel, ticagrelor, cangrelor
Current Vascular Pharmacology
Title: Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
Volume: 8 Issue: 1
Author(s): Carrie S. Oliphant, J. Bradford Doby, Crystal L. Blade, Kanak Das, Debabrata Mukherjee and Pranab Das
Affiliation:
Keywords: P2Y12 receptor antagonists, prasugrel, ticagrelor, cangrelor
Abstract: The use of oral antiplatelet therapy in reducing vascular events has been extensively studied. Currently available oral antiplatelet agents include aspirin and the thienopyridine P2Y12 receptor antagonists. These classes are combined frequently in the setting of acute coronary syndrome and percutaneous coronary intervention (PCI). Resistance to either or both of these agents is a major concern, as antiplatelet resistance has been linked to an increase in thrombotic events and worse clinical outcomes. As a result, there is a need for newer, more effective antiplatelet agents to address the limitations of currently available therapy. Prasugrel, a third generation thienopyridine, has been approved by both the FDA and European Commission. Two additional P2Y12 agents, ticagrelor and cangrelor are in advanced stages of development. The possible advantages of prasugrel over clopidogrel include a faster onset of action, reduced inter-patient variability and more potent platelet inhibition. Ticagrelor is an oral reversible P2Y12 antagonist with greater platelet inhibition compared with clopidogrel. Cangrelor is being developed as an intravenous P2Y12 antagonist with a very fast onset and offset, which may offer advantages particularly in the setting of coronary intervention. These emerging antiplatelet agents may offer advantages such as faster onset of action, greater potency and reversibility of platelet inhibition. This article summarizes the available clinical data on the upcoming P2Y12 antiplatelet agents in the treatment of coronary artery disease.
Export Options
About this article
Cite this article as:
Oliphant S. Carrie, Doby Bradford J., Blade L. Crystal, Das Kanak, Mukherjee Debabrata and Das Pranab, Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226615
DOI https://dx.doi.org/10.2174/157016110790226615 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews Amniotic Fluid Embolism: What Level of Scientific Evidence can be Drawn? A Systematic Review
Current Pharmaceutical Biotechnology Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Current Topics in Medicinal Chemistry Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Structural and Functional Characterization of a γ-Type Phospholipase A2 Inhibitor from Bothrops jararacussu Snake Plasma
Current Topics in Medicinal Chemistry Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Expression of Mastoparan B, a Venom Peptide, Via Escherichia coli C43 (DE3) Coupled with an Artificial Oil Body-Cyanogen Bromide Technology Platform
Protein & Peptide Letters Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique
Current Stem Cell Research & Therapy Magnetic Digital Microfluidics for Point-of-Care Testing: Where Are We Now?
Current Medicinal Chemistry Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Effect of Antipsychotic Drugs on Cerebrovascular Morbidity and Mortality: A Systematic Review
Current Drug Therapy